secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ultragenyx Pharmaceutical Inc. (RARE)
CIK:        0001515673
Form:       8-K
Filed at:   2024-02-15T23:59:59+00:00
Accession:  0000950170-24-015856
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ultragenyx FY2023 revenue $434M (+20% YoY); net loss narrows; 2024 guide $500-530M
--------------------------------------------------------------------------------

- Total revenue 2023 $434M (+20% YoY); Crysvita $328M (+17%), Dojolvi $71M (+27%).
- Net loss 2023 $607M ($8.25/sh) vs $707M ($10.12) in 2022; Q4 loss $123M ($1.52).
- Cash $777M at Dec 31, 2023; 2024 net cash used in ops expected <$400M.
- 2024 guidance: total revenue $500-530M, Crysvita $375-400M, Dojolvi $75-80M.
- Pipeline: DTX401 GSDIa Ph3 data H1 2024; GTX-102 Angelman expansion data H1 2024; setrusumab OI Ph3 enrollment Q1 end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1515673/000095017024015856/0000950170-24-015856-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1515673/000095017024015856/rare-20240215.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-015856

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer